secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001193125-26-159062
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharma amends employment agreements: CEO salary $673,625, CFO salary $501,273
--------------------------------------------------------------------------------

- New employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026.
- CEO Cohen: base salary $673,625, bonus target up to 60%, term through April 15, 2028.
- CFO Moran: base salary $501,273, bonus target up to 40%, term through April 15, 2028.
- CEO severance: 12 months' base salary, COBRA; change-in-control: 24 months, 2x bonus, full vesting.
- CFO severance: 12 months' base salary, COBRA; change-in-control: 18 months, 1x bonus, full vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526159062/0001193125-26-159062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526159062/crbp-20260415.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-159062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer